VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Curon Biopharmaceutical out-licensed global rights for a clinical-stage bispecific candidate to Merck for $700 million upfront plus $600 million in milestones. China Sanjiu Medical & Pharmaceutical ...
IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 ...
(RTTNews) - Biotechnology company IGM Biosciences, Inc. (IGMS), Thursday announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell ...
(RTTNews) - IGM Biosciences, Inc. (IGMS), a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases, on Thursday announced a strategic update. The company will ...
How Does Lunsumio Work for FL? Lunsumio is a special type of molecule that can attach to two different types of cells. This is called a bispecific antibody. It attaches to CD20 proteins on lymphoma ...
Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback